Compare IPHA & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | INGN |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | France | United States |
| Employees | N/A | 753 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 136.1M |
| IPO Year | 2014 | 2013 |
| Metric | IPHA | INGN |
|---|---|---|
| Price | $1.84 | $5.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $5.75 | ★ $11.25 |
| AVG Volume (30 Days) | 33.6K | ★ 257.5K |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,668,000.00 |
| Revenue This Year | $180.36 | $8.03 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.86 |
| 52 Week Low | $1.18 | $5.06 |
| 52 Week High | $2.71 | $9.13 |
| Indicator | IPHA | INGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 29.85 |
| Support Level | $1.67 | N/A |
| Resistance Level | $1.88 | $6.73 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 9.09 | 11.34 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.